Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Torrent Pharma Q3...

    Torrent Pharma Q3 profit jumps over four fold to Rs 246 crore

    GarimaWritten by Garima Published On 2019-01-31T10:35:01+05:30  |  Updated On 31 Jan 2019 10:35 AM IST
    Torrent Pharma Q3 profit jumps over four fold to Rs 246 crore

    Torrent Pharma had posted a net profit of Rs 58 crore in the corresponding period of 2017-18, the company said in a BSE filing.


    Ahmedabad: Drug firm Torrent Pharmaceuticals on Wednesday reported an over four-fold jump in consolidated net profit to Rs 246 crore for the December 2018 quarter.


    It had posted a net profit of Rs 58 crore in the corresponding period of 2017-18, the company said in a BSE filing.


    Consolidated revenue from operations stood at Rs 2,051 crore for the quarter, against Rs 1,463 crore a year ago.


    Read Also: Torrent Pharma issues a voluntary nationwide recall of Losartan Potassium tablets: USFDA


    In a separate filing, the company said its board has approved an interim dividend of Rs 13 per equity share.


    The company said its board has recommended to members to obtain enabling approval for issuance of equity shares including convertible bonds/debentures through a qualified institutional placement and/or depository receipts or any other modes for an amount not exceeding Rs 5,000 crore through postal ballot.


    Read Also: Torrent Pharma Q2 net profit dips 12 percent to Rs 179 crore

    BSEconsolidated revenueconvertible bondsequity sharesinterim dividendTorrentTorrent Pharma q3Torrent Pharma q3 net profitTorrent pharma sharesTorrent Pharmaceuticals
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok